XML 118 R62.htm IDEA: XBRL DOCUMENT
v3.22.4

Revenue (Details) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 USD ($) countries | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($)
Disaggregation of Revenue [Line Items] |  |  |
Emerging Markets total number of countries | countries | 20 |  |
Net sales | $ 12,682 | $ 11,888 | $ 9,913
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price |  |  | 179
Contract with Customer, Liability [Abstract] |  |  |
Contract with Customer, Liability | 509 | 484 |
Change in Contract with Customer, Liability [Abstract] |  |  |
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price |  |  | 179
Contract with Customer, Liability, Revenue Recognized | 156 |  |
UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 7,632 | 6,911 | 5,701
Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 5,111 | 4,978 | 4,212
EMEA [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,526 | 2,518 | 2,097
APAC [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,116 | 2,070 | 1,781
Latin America and Canada [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 469 | 386 | 307
Emerging Markets [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,715 | 1,429 | 1,138
country_US excluding Other Net Sales |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 7,632 | 6,901 | 5,508
Global Endoscopy (Endo) Reporting Unit [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,221 | 2,141 | 1,780
Global Endoscopy (Endo) Reporting Unit [Member] | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,341 | 1,222 | 1,000
Global Endoscopy (Endo) Reporting Unit [Member] | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 880 | 919 | 780
Global Urology and Pelvic Health Reporting Unit [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,773 | 1,583 | 1,286
Global Urology and Pelvic Health Reporting Unit [Member] | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,257 | 1,120 | 918
Global Urology and Pelvic Health Reporting Unit [Member] | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 516 | 463 | 368
Global Neuromodulation (NM) Reporting Unit [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 917 | 909 | 761
Global Neuromodulation (NM) Reporting Unit [Member] | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 715 | 713 | 610
Global Neuromodulation (NM) Reporting Unit [Member] | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 202 | 196 | 151
Global Peripheral Interventions (PI) Reporting Unit [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,899 | 1,820 | 1,577
Global Peripheral Interventions (PI) Reporting Unit [Member] | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,048 | 996 | 888
Global Peripheral Interventions (PI) Reporting Unit [Member] | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 850 | 824 | 689
Interventional Cardiology Therapies |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,228 | 2,209 | 1,975
Interventional Cardiology Therapies | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 744 | 778 | 728
Interventional Cardiology Therapies | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,485 | 1,431 | 1,247
Cardiac Rhythm Management |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,100 | 2,019 | 1,704
Cardiac Rhythm Management | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,337 | 1,214 | 992
Cardiac Rhythm Management | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 763 | 805 | 712
Electrophysiology (EP) |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 585 | 365 | 287
Electrophysiology (EP) | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 275 | 128 | 118
Electrophysiology (EP) | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 310 | 237 | 169
Watchman |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,019 | 829 | 324
Watchman | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 915 | 729 | 253
Watchman | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 103 | 100 | 71
Global Cardiology Reporting Unit |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 5,932 | 5,422 | 4,290
Global Cardiology Reporting Unit | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 3,271 | 2,850 | 2,091
Global Cardiology Reporting Unit | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 2,662 | 2,572 | 2,199
Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | (60) | 13 | 219
Other | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 0 | 10 | 193
Other | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 0 | 4 | 27
MedSurg [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 4,911 | 4,633 | 3,827
MedSurg [Member] | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 3,312 | 3,055 | 2,528
MedSurg [Member] | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 1,599 | 1,578 | 1,299
Cardiovascular [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 7,831 | 7,242 | 5,866
Cardiovascular [Member] | UNITED STATES |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | 4,319 | 3,846 | 2,979
Cardiovascular [Member] | Non-US [Member] |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Net sales | $ 3,512 | $ 3,396 | $ 2,888

X
- Definition Emerging Markets total number of countries + References No definition available. + Details
Name: | bsx_EmergingMarketsTotalNumberOfCountries
Namespace Prefix: | bsx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_ChangeInContractWithCustomerLiabilityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_ContractWithCustomerLiabilityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_EMEAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AsiaPacificMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=bsx_LatinAmericaandCanadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=bsx_EmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=bsx_USExcludingOtherNetSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalEndoscopyEndoReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalUrologyandPelvicHealthReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalNeuromodulationNmReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalPeripheralInterventionsPiReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_InterventionalCardiologyTherapiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_CardiacRhythmManagementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_ElectrophysiologyEPMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_WatchmanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_GlobalCardiologyReportingUnitMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bsx_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_MedsurgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bsx_CardiovascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |